Craig-Hallum Initiates Coverage On Soleno Therapeutics with Buy Rating, Announces $8 Price Target

Craig-Hallum initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with a Buy rating and a $8 price target.

Benzinga · 01/10/2020 15:15

Craig-Hallum initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with a Buy rating and a $8 price target.